English

Communiqué from Genovis AB (publ) Annual General Meeting May 16, 2023

Report this content

The Board withdrew its proposal regarding authorizing the Board of Directors to decide on the issuance of shares, item 17 in the notice.

The Annual General Meeting adopted the following resolutions:

  • The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.
  • The Board and the Chief Executive Officer were discharged from liability.
  • The Board shall consist until the next AGM of five ordinary members without deputies.
  • Re-election of Board members Torben Jørgensen, Mikael Lönn, Lotta Ljungqvist, Steve Jordan and Magnus Gustafsson.

Torben Jørgensen was elected Chairperson of the Board.

  • Remuneration will be paid to the Board of Directors in the amount of SEK 200,000 to Board members and SEK 400,000 to the Chairperson of the Board. 
  • Remuneration to the auditors will be paid on approved account.  
  • In accordance with the Nomination Committee’s proposal, the Meeting re-elected the accounting firm Öhrlings PricewaterhouseCoopers AB as auditor for the period until the close of the Annual General Meeting 2024.
  • In accordance with the Board’s proposal the Company's Articles of Association, item 2 and 8, was amended. The Board shall be seated in the Municipality of Kävlinge and the company’s General Meeting can be held at the following locations, Kävlinge and Lund.
  • A Nomination Committee will be formed with representatives of the four largest shareholders at September 30, 2023.

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: +46 (0)70-276 46 56 fredrik.olsson@genovis.com

Genovis’ business concept is to apply its knowledge and customer driven innovation to design and provide tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.se, tel: +46 (0)8-463 83 00.

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

Subscribe

Documents & Links